BOSTON SCIENTIFIC CORP Earnings Summary — Q1 2026

• Revenue grew 11.58% YoY to $5.20 billion, maintaining strong double-digit momentum despite a slight sequential seasonal dip.
• Net income surged nearly 100% YoY to $1.34 billion, driven by significant non-operating income and improved operational leverage.
• Operating income reached $1.10 billion, a substantial increase from $825 million in the prior quarter, reflecting margin expansion initiatives.
• Research & Development investment remains high at $516 million, supporting the company's pivot toward high-growth MedTech categories.
• The company has successfully transitioned from a stent-dependent business to a diversified leader in cardiovascular and endoscopy segments.
• Gross profit margins remain robust at approximately 69.5%, consistent with the shift toward innovative, higher-margin interventions.

Management remains focused on high-growth adjacent markets through disciplined R&D and M&A, aiming for sustained margin expansion toward an 18% annual operating margin target.

Improving

The dramatic jump in net income and continued double-digit revenue growth suggest the company is entering a high-performance phase following its strategic repositioning.

Boston Scientific is positioned as an elite MedTech compounder, with a clear trajectory for sustained double-digit revenue growth and EPS expansion driven by structural heart and electrophysiology pipelines.